For a multi-billion dollar drug with an opportunity to have patient-driven prescriptions, it's surprising that it's taken this long for Astrazeneca to finally get around to a DTC TV campaign for Seroquel XR. Given that the ad is so depression-focused I wonder if the marketing team at AZ had been making this ad for the depression indication for which they're still waiting on FDA approval. If you mute the ad and just look at it, it could easily be an ad for any of the products currently advertising for major depression. I wonder if they just got tired of waiting on the approval and had the ad agency change the voiceover to accomodate the comparable indication that they do have in bipolar depression. Just an outsider's guess.
The ad itself is pretty depressing. I know the Abilify ads were criticized for being too "sunny" in their conclusions, but geez this ad could use a little. If I wasn't depressed before viewing it, I sure am now. The fair balance is rough too. All 53 seconds of it. It's always hard to hear the drug you're taking has an increased risk of DEATH.
The one thing this ad will accomplish if it doesn't get lost in the other 85 seconds is that some patients can take just 1 pill. It's the last thing we hear before the fair balance kicks in. This of course is basically the only advantage of Seroquel XR over it's soon-to-be-generic parent Seroquel. However, the suggestion is erroneous. Patients suffering from Bipolar disorder rarely can take a single medication to control their systems, esp. given the associated comorbidities to manage as well as the drugs to counter act the side effects of Seroquel. Still, the 1 pill promise could drive patients to talk to their doctor about Seroquel which is the first step in this ad paying off for AZ. It will be interesting to see if their print campaign is revised to coincide with the TV spot as well as whether AZ will seek better ad spot availability by creating a 60 second version.
Wednesday, December 2, 2009
Astrazeneca's Seroquel Bipolar Depression DTC TV Ad Hits the Airwaves
Labels:
Abilify,
ads,
antipsychotic,
Astrazeneca,
atypical,
bipolar,
bristol-Myers Squibb,
FDA,
generic,
major depressive disorder
Subscribe to:
Posts (Atom)